Windward Capital Management Co. CA lifted its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,768 shares of the company’s stock after purchasing an additional 2,755 shares during the period. Johnson & Johnson comprises about 1.9% of Windward Capital Management Co. CA’s investment portfolio, making the stock its 22nd largest position. Windward Capital Management Co. CA’s holdings in Johnson & Johnson were worth $13,101,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also added to or reduced their stakes in the stock. Landmark Financial Advisors LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after acquiring an additional 7 shares during the period. Paradigm Financial Advisors LLC lifted its stake in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after acquiring an additional 9 shares during the period. Premier Asset Management LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after acquiring an additional 12 shares during the period. Lbmc Investment Advisors LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after acquiring an additional 14 shares during the period. Finally, Halbert Hargrove Russell LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after acquiring an additional 15 shares during the period. 67.21% of the stock is owned by institutional investors.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson (JNJ) opened at $127.38 on Friday. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The stock has a market cap of $351,969.94, a PE ratio of 17.97, a PEG ratio of 2.09 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 861.54%.
A number of analysts recently weighed in on JNJ shares. BTIG Research reaffirmed a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective for the company. in a research note on Monday, January 8th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets increased their price target on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, Wells Fargo reissued an “outperform” rating and set a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $146.06.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Shares Bought by Windward Capital Management Co. CA” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/03/23/johnson-johnson-jnj-shares-bought-by-windward-capital-management-co-ca.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.